Bard
This article was originally published in The Gray Sheet
Executive Summary
Appoints Gerald Messerschmidt, MD, to the newly created post of vice president, scientific affairs. Messerschmidt, 43, will have company-wide responsibility for "medical and clinical affairs, regulatory affairs, quality assurance and environmental health and safety," the firm states in a Jan. 12 announcement. Bard agreed to create such a post under a deal reached in October settling numerous criminal and civil charges related to the firm's USCI angioplasty operations ("The Gray Sheet" Oct. 18, p. 3). The new exec, who will answer to President and Chief Operating Officer William Longfield, most recently served as VP, medical and regulatory affairs at Princeton-based DNX Corp
You may also be interested in...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.